Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

被引：0

作者：

Bing Li

Ke Fan

Tonghe Zhang

Zhifeng Wu

Siming Zeng

Mingwei Zhao

Qian Ren

Dongping Zheng

Lifei Wang

Xiaoling Liu

Mei Han

Yanping Song

Jian Ye

Cheng Pei

Jinglin Yi

Xian Wang

Hui Peng

Hong Zhang

Zhanyu Zhou

Xiaoling Liang

Fangliang Yu

Miaoqin Wu

Chaopeng Li

Chunling Lei

Jilong Hao

Luosheng Tang

Huiping Yuan

Shanjun Cai

Qiuming Li

Jingxiang Zhong

Suyan Li

Lin Liu

Min Ke

Jing Wang

Hui Wang

Mengli Zhu

Zenghua Wang

Yang Yan

Feng Wang

Youxin Chen

机构：

[1] Peking Union Medical College Hospital,Ophthalmology Department

[2] Henan Provincial Eye Hospital,Ophthalmology Department

[3] Jinan Second People’s Hospital,Ophthalmology Department

[4] Wuxi Second People’s Hospital,Ophthalmology Department

[5] Guangxi Zhuang Autonomous Region People’s Hospital,Ophthalmology Department

[6] Peking University People’s Hospital,Ophthalmology Department

[7] Shijiazhuang People’s Hospital,Ophthalmology Department

[8] Shanxi Ophthalmic Hospital,Ophthalmology Department

[9] Hebei Eye Hospital,Ophthalmology Department

[10] Eye Hospital,Ophthalmology Department

[11] WMU Zhejiang Eye Hospital,Ophthalmology Department

[12] Tianjin Eye Hospital,Ophthalmology Department

[13] General Hospital of Central Theater Command,Ophthalmology Department

[14] Army Medical Center of PLA,Ophthalmology Department

[15] The First Affiliated Hospital of Xi’an Jiaotong University,Ophthalmology Department

[16] Affiliated Eye Hospital of Nanchang University,Ophthalmology Department

[17] The Affiliated Hospital of Guizhou Medical University,Ophthalmology Department

[18] The First Affiliated Hospital of Chongqing Medical University,Ophthalmology Department

[19] The First Affiliated Hospital of Harbin Medical University,Ophthalmology Department

[20] Qingdao Municipal Hospital,Ophthalmology Department

[21] Zhongshan Ophthalmic Center,Ophthalmology Department

[22] Sun Yat-Sen University,Ophthalmology Department

[23] The First Hospital of Nanchang,Ophthalmology Department

[24] Zhejiang Provincial People’s Hospital,Ophthalmology Department

[25] Huai’an First People’s Hospital,Ophthalmology Department

[26] Xi’an People’s Hospital,Ophthalmology Department

[27] First Hospital of Jilin University,Ophthalmology Department

[28] The Second Xiangya Hospital of Center South University,Ophthalmology Department

[29] The Second Affiliated Hospital of Harbin Medical University,Ophthalmology Department

[30] Affiliated Hospital of Zunyi Medical University,Ophthalmology Department

[31] The First Affiliated Hospital of Zhengzhou University,Ophthalmology Department

[32] The First Affiliated Hospital of Jinan University,Ophthalmology Department

[33] Xuzhou First People’s Hospital,Ophthalmology Department

[34] Renji Hospital Affiliated to Shanghai Jiaotong University,Clinical Research Center

[35] Wuhan University Zhongnan Hospital,Ophthalmology Department

[36] Qilu Pharmaceutical Co.,undefined

[37] Ltd.,undefined

[38] The Second Affiliated Hospital of Xi’an Jiaotong University,undefined

来源：

Ophthalmology and Therapy | 2024年 / 13卷

关键词：

Neovascular age-related macular degeneration; QL1207; Aflibercept; Biosimilar;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：353 / 366

页数：13

共 50 条

[1] Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial
Li, Bing
Fan, Ke
Zhang, Tonghe
Wu, Zhifeng
Zeng, Siming
Zhao, Mingwei
Ren, Qian
Zheng, Dongping
Wang, Lifei
Liu, Xiaoling
Han, Mei
Song, Yanping
Ye, Jian
Pei, Cheng
Yi, Jinglin
Wang, Xian
Peng, Hui
Zhang, Hong
Zhou, Zhanyu
Liang, Xiaoling
Yu, Fangliang
Wu, Miaoqin
Li, Chaopeng
Lei, Chunling
Hao, Jilong
Tang, Luosheng
Yuan, Huiping
Cai, Shanjun
Li, Qiuming
Zhong, Jingxiang
Li, Suyan
Liu, Lin
Ke, Min
Wang, Jing
Wang, Hui
Zhu, Mengli
Wang, Zenghua
Yan, Yang
Wang, Feng
Chen, Youxin
OPHTHALMOLOGY AND THERAPY, 2024, 13 (01) : 353 - 366
[2] Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration A Phase III Randomized Trial
Hamouz, Jan
Nowosielska, Agnieszka
Swiech-Zubilewicz, Anna
Abengoechea, Santiago
Baumane, Kristine
Vajas, Attila
Siewierska, Malgorzata
Veselovsky, Milan
Veith, Miroslav
Kerenyi, Agnes
Mange, Shobhana
Baidya, Krishnapada
Laganovska, Guna
Juergens, Ignasi
Papp, Andras
Gosai, Jignesh
Stefanickova, Jana
Han, Mei
Fryczkowski, Piotr
Zalewski, Dominik
Wang, Jing
Wei, Wenbin
OPHTHALMOLOGY RETINA, 2025, 9 (04): : 343 - 351
[3] Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
Mishra, Sanjay Kumar
Kumar, Pradeep
Khullar, Srishti
Joshi, Amrita
Sati, Alok
Kumar, Sonali Vinay
Unni, Deepesh
Kumar, Atul
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS, 2022, 8 (01)
[4] Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
Sanjay Kumar Mishra
Pradeep Kumar
Srishti Khullar
Amrita Joshi
Alok Sati
Sonali Vinay Kumar
Deepesh Unni
Atul Kumar
International Journal of Retina and Vitreous, 8
[5] EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Bordon, Arnaldo F.
Kaiser, Peter K.
Wolf, Armin
Cen, Liyi
Heyn, Jens
Urosevic, Dragan
Dodeller, Francis
Allmannsberger, Lisa
Silva, Rufino
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2024, 44 (10): : 1704 - 1713
[6] Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Loewenstein, Anat
Czumbel, Norbert
Ernest, Jan
Dusova, Jaroslava
Pearlman, Joel
Nowosielska, Agnieszka
OPHTHALMOLOGY RETINA, 2023, 7 (09): : 753 - 761
[7] Evaluating the Efficacy and Safety of Aflibercept Biosimilar (P041) Compared with Originator Product in Patients with Neovascular Age-Related Macular Degeneration
Karkhaneh, Reza
Faghihi, Hooshang
Riazi-Esfahani, Hamid
Abrishami, Mojtaba
Bazvand, Fatemeh
Ebrahimiadib, Nazanin
Johari, Mohammadkarim
Akhlaghi, Mohammadreza
Shoeibi, Nasser
Norouzzadeh, Mohammad Hossein
Astaneh, Mohammad Reza Ansari
Khojasteh, Hassan
Fooladi, Marjan Imani
Khodabande, Alireza
Ghassemi, Fariba
Pour, Elias Khalili
Zarei, Mohammad
Mirshahi, Ahmad
Fazel, Farhad
Ashraf, Hossein
Hosseini, Seyedeh Maryam
Dourandeesh, Maryam
Feghhi, Mostafa
Alizadeh, Yousef
Behboudi, Hassan
Azadi, Pejvak
Sabzvari, Araz
Kafi, Hamidreza
Falavarjani, Khalil Ghasemi
OPHTHALMOLOGY RETINA, 2024, 8 (08): : 744 - 753
[8] The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
Musial-Kopiejka, Magdalena
Polanowska, Katarzyna
Dobrowolski, Dariusz
Krysik, Katarzyna
Wylegala, Edward
Grabarek, Beniamin Oskar
Lyssek-Boron, Anita
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (04)
[9] Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration
Holz, Frank G.
Oleksy, Piotr
Ricci, Federico
Kaiser, Peter K.
Kiefer, Joachim
Schmitz-Valckenberg, Steffen
OPHTHALMOLOGY, 2022, 129 (01) : 54 - 64
[10] EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The ARIES Study: A Randomized Clinical Trial
Mitchell, Paul
Holz, Frank G.
Hykin, Philip
Midena, Edoardo
Souied, Eric
Allmeier, Helmut
Lambrou, George
Schmelter, Thomas
Wolf, Sebastian
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (09): : 1911 - 1920

← 1 2 3 4 5 →